Sanoculis Announces CE Mark Approval of MINT, a Novel Stent-Free Minimally Invasive Glaucoma Surgery Technology

Apr 21, 2025 22:15 CST Updated 22:15

Sanoculis

Medical Device Developer

SanoculisAnnouncing its innovative stent-free technology---MINT（Minimally Invasive Nasal Trabeculostomy) has been approved by CE for marketing,MINTCan be used for the treatment of adult patients undergoing glaucoma angle surgery.SanoculisWill beSelective commercial pre-launch promotion for MINT to be conducted later this year.

Executive Evaluation

"MINT represents a significant innovation in the field of minimally invasive glaucoma surgery (MIGS), with notable potential to improve patient outcomes and elevate treatment standards. Clinical data from our prospective single-arm study (with two-year follow-up) demonstrates that MINT is both safe and effective in reducing intraocular pressure (IOP), while also decreasing the need for glaucoma medications."

---Nir Israeli Co-founder and CEO of Sanoculis

Globally, there are currently 76 million glaucoma patients, and this number is expected to increase to 112 million by 2040.Glaucoma has become the second leading cause of irreversible blindness globally. Most glaucoma progresses chronically, and if not diagnosed or treated in time, it will lead to irreversible vision loss. Early detection and treatment are crucial for preserving visual function, as optic nerve damage can cause progressive visual field defects. Currently, reducing intraocular pressure and slowing the progression of visual field defects remain the only proven effective treatment methods, though some technical shortcomings still exist.Traditional treatment options include trabeculectomy and catheter shunt implantation, while in recent years, microMicro-invasive Glaucoma Surgery (MIGS)Progress has provided simpler and safer options.Despite improvements in the incidence of complications with existing devices, achieving the required IOP control for moderate to severe patients remains challenging.

Therefore, likeSanoculis、Bausch + Lomb (Elios Vision）、Glaukos、Companies like MINIject are developing innovative treatment technologies to address traditional issues.Traditional treatment options are insufficient.

MINT

MINTMultiple openings are created in the nasal trabecular meshwork, allowing aqueous humor to flow through the channels into the trabecular meshwork and then exit.Schlemm'sTube drainage, thereby achieving the purpose of lowering intraocular pressure.

MINTUtilizing a unique mechanical semi-automatic trephine technology, equipped with a state-of-the-art 0.14mm diameter instrument, precise openings can be created in the pigmented trabecular meshwork.

SanoculisPublishMINTClinical research data shows：Patients with open-angle glaucoma are satisfied with the minimally invasive MINT anti-glaucoma surgery. The efficacy and safety (0% serious adverse events) results are similar to other trabecular bypass surgeries. However, MINT is simpler and faster than most other procedures.

MINT Study

Sanoculis

SanoculisSanoculis Ltd. is a company focused on innovation in ophthalmic medical devices, having developed a proprietary stent-free minimally invasive solution for sclerostomy and trabeculotomy in glaucoma angle surgery.SanoculisCommitted to providing an innovative stent-free technology platform to raise the standard of glaucoma diagnosis and treatment and improve patient outcomes.